D. Boral Capital Reiterates Buy Rating for Anavex Life Sciences (NASDAQ:AVXL)

Anavex Life Sciences (NASDAQ:AVXL - Get Free Report)'s stock had its "buy" rating reiterated by investment analysts at D. Boral Capital in a report issued on Monday,Benzinga reports. They presently have a $46.00 price objective on the biotechnology company's stock. D. Boral Capital's price objective indicates a potential upside of 419.19% from the company's previous close.

Separately, HC Wainwright reissued a "buy" rating and set a $42.00 price objective on shares of Anavex Life Sciences in a research note on Monday, March 31st.

Anavex Life Sciences Stock Performance

NASDAQ:AVXL traded up $0.32 during mid-day trading on Monday, hitting $8.86. 699,638 shares of the company's stock traded hands, compared to its average volume of 1,263,729. The company has a market cap of $753.67 million, a PE ratio of -16.11 and a beta of 0.80. The firm's 50 day simple moving average is $8.70 and its 200 day simple moving average is $8.52. Anavex Life Sciences has a 1 year low of $3.25 and a 1 year high of $14.44.

Anavex Life Sciences (NASDAQ:AVXL - Get Free Report) last issued its quarterly earnings data on Wednesday, February 12th. The biotechnology company reported ($0.14) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.17) by $0.03. On average, research analysts expect that Anavex Life Sciences will post -0.69 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently modified their holdings of AVXL. Vermillion Wealth Management Inc. purchased a new stake in shares of Anavex Life Sciences during the 4th quarter valued at about $34,000. Tower Research Capital LLC TRC raised its stake in shares of Anavex Life Sciences by 102.0% during the fourth quarter. Tower Research Capital LLC TRC now owns 3,383 shares of the biotechnology company's stock valued at $36,000 after purchasing an additional 1,708 shares during the period. Orion Capital Management LLC lifted its position in shares of Anavex Life Sciences by 666.7% during the third quarter. Orion Capital Management LLC now owns 11,500 shares of the biotechnology company's stock worth $65,000 after purchasing an additional 10,000 shares in the last quarter. PVG Asset Management Corp purchased a new position in shares of Anavex Life Sciences in the third quarter valued at $74,000. Finally, BNP Paribas Financial Markets grew its holdings in Anavex Life Sciences by 97.0% during the 3rd quarter. BNP Paribas Financial Markets now owns 15,074 shares of the biotechnology company's stock valued at $86,000 after purchasing an additional 7,421 shares in the last quarter. Institutional investors and hedge funds own 31.55% of the company's stock.

About Anavex Life Sciences

Anavex Life Sciences Corp., a clinical stage biopharmaceutical company, engages in the development of therapeutics for the treatment of central nervous system diseases. Its lead product candidate is ANAVEX 2-73 for the treatment of Alzheimer's disease and Parkinson's disease, as well as other central nervous system diseases, including rare diseases, such as Rett syndrome, a rare severe neurological monogenic disorder; and infantile spasms, Fragile X syndrome, and Angelman syndrome.